27-28 June 2022
Tackling ethical, economical, legal, and social aspects of Personalised Medicine Conference
In 2014, the Horizon 2020 Advisory Group has defined PM as a medical model using characterization of individuals’ phenotypes and genotypes (e.g., molecular profiling, medical imaging and lifestyle data) to tailor the right therapeutic strategy to the right person at the right time, determine the predisposition to disease and deliver timely and targeted prevention. The definition has been adopted by the European Council Conclusion on PM for patients, which specified that “Personalised medicine relates to the broader concept of patient-centered care, which takes into account that, in general, healthcare systems need to better respond to patient needs” (2015/C 421/03).
While more and more countries are introducing whole genome sequencing and Personalised Medicine approaches into clinical care (i.e., the United Kingdom’s National Health Service plan to sequence 5 million genomes in 5 years and France and Canada which, at various stages, are kicking off publicly funded genomic healthcare services), the awareness about the ethical, economic, legal and social implication of Personalised Medicine are becoming central in the public discourse.
The focus of this Conference will, therefore, be on the following topics:
- Ethical aspects
- Public trust
- The economic value of Personalised Medicine
- Diversity, inclusion and Personalised Medicine
- Sex, gender and Personalised Medicine
For more information register: https://www.regions4permed.eu/eventi/tackling-ethical-economical-legal-and-social-aspects